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negatively correlated with utility. The greater the disease 
activity, the lower the utility and the greater the indirect 
costs.
Keywords Quality of life · Indirect costs · Productivity 
loss · Psoriatic arthritis
Introduction
Psoriatic arthritis (PsA) is one of the most prevalent inflam-
matory joint diseases, occurring in 11.2 % (5.9–23.9 %) of 
patients with psoriasis (affecting approximately 2 % of the 
population) [1, 2]. The disease occurs when the immune 
system of a patient affected with psoriasis attacks its own 
joints, which leads to severe pain, severe joint destruction, 
mutilating arthritis and co-morbidities [3, 4].
Rheumatic diseases are a major cause of disability and 
generate significant socio-economic costs. People affected 
with PsA require lifelong treatment, which causes great 
direct costs to the national health insurance system. Severe 
pain and joint destruction reduce the quality of life, which 
is a huge burden for the patient; moreover, the disease 
can reduce the ability to work, can cause interruptions in 
employment and can decrease productivity. The value of 
lost productivity is an indirect cost, that is, the cost not due 
to expenses but due to the lack of work caused by disease.
The indirect costs that follow PsA are associated with 
two types of indirect costs (generated productivity loss): 
absence from work (absenteeism) and a decrease in the effi-
ciency of work performed by a sick patient (presenteeism). 
Absenteeism refers to the number of days on sick leave, 
periods of unemployment caused by disease and leaving 
the labour market prematurely due to sickness (e.g. early 
disability pension or premature death). Presenteeism refers 
Abstract The aim of the study was to assess the indirect 
costs, health-related quality of life and clinical character-
istics of patients with psoriatic arthritis (PsA), measured 
using a PsA disease activity index in Poland. Additionally, 
we aimed to investigate the association between the activ-
ity, utility of PsA-affected patients and productivity loss in 
a Polish setting. A questionnaire survey was conducted to 
assess disease activity, as well as productivity loss, and a 
paper version of the EuroQoly-5D-3L questionnaire was 
used to assess productivity loss and the quality of life. Indi-
rect costs were assessed with the human capital approach 
employing the gross domestic product (GDP) per capita, 
gross value added (GVA) and gross income (GI) per worker 
in 2014 in Poland and were expressed in Polish zlotys 
(PLN) as well as in euros. The correlation was presented 
using the Spearman correlation coefficient. Our analysis 
was performed on the basis of 50 full questionnaires col-
lected. We observed a mean utility value of 0.6567. The 
mean number of days off work was 2.88 days per month, 
and mean on-the-job productivity loss was 24.1 %. Aver-
age monthly indirect costs per patient were €206.7 (864.01 
PLN) calculated using the GDP; €484.56 (2025.46 PLN) 
calculated using the GVA; and €209.70 (876.56 PLN) cal-
culated using the GI. PsA reduces the patients’ quality of 
life as well as their productivity loss associated with both 
absenteeism and presenteeism. Total indirect costs were 
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to a situation when a sick person is present at work, but his 
or her productivity is lower than average due to disease. 
Productivity loss due to lower efficiency of work has been 
studied since the early 1990s, but it is commonly excluded 
in studies on indirect costs owing to difficulties in the esti-
mation of lower productivity.
Both absenteeism and presenteeism data can be obtained 
in a questionnaire survey using well-validated tools, such 
as the Work Productivity and Activity Impairment (WPAI) 
questionnaire. It is a standard analytical tool commonly 
used to measure impairments in work and activities [5]. 
Each category of indirect costs (absenteeism and presentee-
ism) can be calculated using two methods: the human capi-
tal approach (HCA) and the friction cost approach (FCA). 
The HCA converts the gross income (GI) that will not be 
generated in the future due to disease into real costs from 
a social perspective; hence, it assumes that a decrease in 
productivity is permanent (irreplaceable). The FCA takes 
into account the productivity loss until a new person is 
employed as a substitute for the sick one.
The EuroQol 5 dimensions 3 level version (EQ-5D-3L) 
questionnaire is a standardised instrument for use as a 
measure of the quality of life. It takes into account 5 most 
important aspects of life: mobility, self-care, housekeeping 
activities, pain and anxiety. For each domain, the patient 
can report the lack of problems (represented by digit 1), 
the occurrence of some problems (represented by digit 2) 
and the occurrence of many problems (represented by digit 
3). A quality-of-life state is created by combining answers 
from all 5 domains, for example, the “1, 3, 2, 2, 2” state 
represents the lack of problems with mobility, many prob-
lems with self-care and some problems concerning the 
remaining 3 domains. Data obtained using the EQ-5D-3L 
questionnaire can be presented as the health state combined 
from all domains or can be converted into utility using pop-
ulation tariffs [6, 7].
Objective
The aim of this study was to assess the indirect costs, 
health-related quality of life and clinical characteristics of 
patients with PsA, measured using a PsA disease activ-
ity index in Poland. The second aim was to investigate 
the association between disease activity and the quality of 
life and productivity loss of patients with PsA in a Polish 
setting.
Materials and methods
A questionnaire-based, multicentre, cross-sectional survey 
was used to collect data on disease activity, health-related 
quality of life and productivity loss of patients with PsA in 
Poland. The survey was conducted from November until 
December 2015 (cut-off date, 31 December 2015). Volun-
teers aged 18 years or older with a diagnosis of PsA from 
randomly selected inpatient and outpatient medical centres 
in Poland were enrolled in the study. The randomisation 
was performed to get a sample of patients with the greatest 
representativeness for Polish population; the whole country 
was divided into 5 regions, and in each of these regions, the 
random selection of medical centres engaged in PsA ther-
apy was performed; then, data obtained by doctors from 
these selected centres were collected.
The questionnaire consisted of two parts: the first one 
was designed to be completed by clinicians and the second 
one—by patients. Both parts were designated with a match-
ing blank patient’s acronym/number assigned by clinicians. 
After enrolment to the study, clinicians completed data 
regarding the disease activity index as well as the current 
pharmacological regimen for each individual patient. In the 
second part of the questionnaire, respondents provided gen-
eral demographic data (basic patient’s characteristics: age, 
sex, size of the place of residence, age at disease diagnosis, 
co-morbidities) as well as responded to a number of ques-
tions referring to the current health state related to PsA and 
reflecting self-assessment of disease activity; utility was 
assessed using the EQ-5D-3L questionnaire, including the 
visual analogue scale (VAS) assessment.
There are no specific scales validated to assess the 
disease activity of PsA. Therefore, disease activity was 
assessed with our own questionnaire developed on the 
basis of the Bath Ankylosing Spondylitis Disease Activ-
ity Index (BASDAI), which is used to measure the activity 
of ankylosing spondylitis [8]. In our assessment of disease 
activity, we considered the major symptoms of PsA such 
as tiredness, joint pain, discomfort in the areas tender to 
touch or pressure, as well as morning joint stiffness and 
its duration, which were assessed in the week preceding 
the day of completing the questionnaire. For each domain, 
patients reported the extent of a health problem on a scale 
from 0 to 10: the higher the value, the greater the activity 
of the disease. Additionally, for each individual patient, we 
assessed the overall disease activity, tiredness and effort, 
and joint pain due to the disease on the same scale, from 
0 to 10. Some questions regarding direct medical costs 
associated with PsA therapy were also included such as a 
monthly range of out-of-pocket expenses on medical and 
nonmedical resources (e.g. private medical consultations, 
formal and informal care, and over-the-counter medica-
tion). A number of questions referring to productivity loss 
(presenteeism, absenteeism), impairment of usual activi-
ties, informal care and benefits taken from a social care 
institution according to the WPAI questionnaire were also 
implemented.
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The HCA was used to estimate indirect costs due to 
absenteeism and presenteeism. Three macroeconomic indi-
cators for Poland were considered: gross domestic prod-
uct (GDP) per capita (equal to €10,688 or 44,677 PLN), 
gross value added (GVA) per worker (equal to €25,055 
or 104,728 PLN) and GI per worker (equal to €10,843 
or 45,325 PLN), presented in 2014 prices in euro (the 
exchange rate was 1 euro = 4.18 PLN) with a correction 
factor of 0.65 (the conventional mean value of output elas-
ticity of labour according to the Cobb–Douglas function 
of production; this approach is suggested by the European 
Commission because increasing the amount of a single fac-
tor of production, with all the other factors of production 
constant, decreases the marginal output of production) [9, 
10]. The GDP per capita is a commonly used measure of a 
country’s economic development; it is a standard method 
of calculations used on a regular basis as revealed in a lit-
erature. The GVA is an increase of value of production due 
to work performed by a human capital. It reflects true eco-
nomic development in areas of production and is expressed 
as value per worker; hence, it does not consider economi-
cally inactive people. Finally, the GI is a macroeconomic 
indicator that best reflects the patient’s perspective regard-
ing lost productivity; however, it does not consider several 
types of job contracts. Assessing indirect costs using the GI 
is particularly important for patients because it reflects lost 
earnings.
Continuous variables were summarised using means 
and standard deviations and medians with the first and the 
third quartiles due to skewness, while nominal variables 
were summarised using counts and percentages. The Spear-
man’s correlation coefficient was used to present the asso-
ciation between disease activity, quality of life, as well as 
absenteeism and presenteeism. Variables of at least ordinal 
scale were compared using the Mann–Whitney U test. P 
values of <0.05 indicated statistical significance. Statistical 
analyses were performed using JMP® 9.0.0 and R® 3.2.2 
software.
Results
We obtained 50 completed questionnaires from patients 
aged from 18 to 84 years (average age, 45.54 years; SD 
13.89). The basic characteristics of the population are pre-
sented in Table 1.
Clinical experts evaluated the activity of PsA for 49 of 
50 patients; 24 patients (49 %) were shown to have disease 
remission (or very low activity) and 25 patients (51 %)—
active disease. All patients provided data on disease activity 
on the VAS based on the modified BASDAI scale. Patients 
reported median values of: 40 % (Q1–Q3: 20–60 %) on the 
scale regarding tiredness; 40 % (Q1–Q3: 20–70 %) on the 
scale regarding pain with affected joints; 40 % (Q1–Q3: 
10–60 %) on the scale regarding discomfort in the areas 
tender to touch or pressure; and 35 % (Q1–Q3: 10–60 %) 
on the scale regarding discomfort at the moment of wak-
ing up (joint stiffness) and during 30 min (15–60 min) of 
morning stiffness. Based on those values, we calculated a 
disease activity score of 3.1 (Q1–Q3: 1.48–4.68) (Table 2).
Data on the quality of life were also reported by all 
respondents, except for the quality of life measured on the 
VAS, which was missing for 1 patient.
Based on data from Table 3, the health states were cre-
ated. The most common state was “1, 1, 1, 1, 1”, reported 
by 12 patients (24 %), followed by “2, 2, 2, 2, 2”, reported 
by 8 patients (16 %). The highest (worse) states observed 
were “3, 3, 3, 2, 2” and “3, 2, 3, 3, 2”, which occurred in 1 
patient each (4 %).
Table 1  Basic characteristics of patients included in the study
Characteristic Value for sample
Age (years) 45.5 (35.75–53.5)
Male 21 (42 %)
Age at onset (years) 36.5 (29–44)
Place of living
 City 43 (86 %)
 Village 7 (14 %)
Table 2  Patient-reported and 
physician-reported disease 
activity
Median with the first and the third quartile
Domain Disease activity assessed by expert 
clinician
P value
Remission/mild Active
Tiredness 2 (1–3.75) 6 (4–7) <0.0001
Pain 2 (1–2) 7 (5–8) <0.0001
Discomfort from areas tender to touch or pressure 1.5 (1–4) 6 (4–7) <0.0001
Morning joint stiffness 1.5 (0.25–2) 6 (4–7) <0.0001
Morning joint stiffness duration (min) 15 (7.75–27.5) 60 (33.5–77.5) <0.0001
Disease activity score 1.5 (0.9–2.4) 4.6 (3.4–5.4) <0.0001
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The mean utility was 0.6567 (SD 0.2738), the low-
est calculated value was 0.004, and the highest calculated 
value was 1.
Patients reported between 0 and 3 consultations with a 
clinician in a month before completing the questionnaire 
(mean 1.22; SD 0.65), of which from 0 to 3 were private 
consultations (mean 0.51; SD 0.73). The mean cost of con-
sultation was €17.42 (SD €16.51) or 72.8 PLN (SD 69.01). 
Of all working patients, 58 % spent from €0 to €23.92 (100 
PLN) monthly on drugs prescribed by a clinician and none 
of them spent more than €143.54 (600 PLN) monthly. A 
similar amount of money was spent on dietary supplements 
and other medicines that were not prescribed by a clinician. 
The smallest amount of money was spent monthly on infor-
mation materials about the disease: more than 90 % of the 
patients spent from €0 to €23.92 (100 PLN) and none of the 
patients spent more than €47.85 (200 PLN).
Data on employment status were collected for all 
patients, of which 32 (64 %) were currently working. 
Among all working patients, 27 (84 %) were on a full-time 
contract. Only 2 patients (4 %) were still studying and only 
6 patients were on pension, of which 3 due to the disease. 
Five patients were retired and thus not considered as eco-
nomically active. The average monthly number of days off 
work was 3.88 (SD 6.19), with the minimum and maxi-
mum values of 0 and 24, respectively. Most respondents 
(37.5 %) reported lack of days off work due to the disease. 
More than a half of the patients reported less than 2 days 
on sick leave in a month. The mean on-the-job productivity 
loss was 24.1 % (SD 22.27 %), which represents the extent 
of presenteeism. The minimal reported value was 0 % and 
the maximum—70 %. Data were presented for all working 
patients with PsA.
As a main analysis, we used the GDP per capita and 
obtained the monthly indirect costs of €67.4 (SD €116.75) 
or 281.73 PLN (SD 488.02 PLN) for absenteeism and of 
€139.31 (SD €128.92) or 582.32 PLN (SD 538.89 PLN) 
for presenteeism. Taking into account the GVA per worker, 
we obtained the costs of €158 (SD €273.69) or 660.44 
PLN (SD 1144.02 PLN) for absenteeism and of €326.56 
(SD €302.21) or 1365.02 PLN (SD 1263.24 PLN) for 
presenteeism. Considering the GI per worker, we obtained 
monthly indirect costs of €68.38 (SD €118.44) or 285.81 
PLN (SD 495.08 PLN) for absenteeism and of €141.33 (SD 
€130.79) or 590.74 PLN (SD 546.69 PLN) for presentee-
ism. The average monthly indirect cost of both absentee-
ism and presenteeism per patient was €206.7 (SD €203.24) 
or 864.01 PLN (SD 849.54 PLN) calculated using GDP; 
€484.56 (SD €476.44) or 2025.46 PLN (SD 1991.52 PLN) 
calculated using the GVA; and €209.70 (SD €206.19) or 
876.56 PLN (SD 861.87 PLN) calculated using the GI. 
Data were based on answers of 32 working patients with 
PsA. The cost of presenteeism constituted 67.4 % of the 
total indirect costs.
As a sensitivity analysis, the results without the cor-
rection factor (marginal productivity of labour) were 
also presented. The total annual indirect costs per patient 
were €318.01 (SD €312.68) or 1329.28 PLN (SD 1307 
PLN) calculated using the GDP; €745.48 (SD €732.99) or 
3116.11 PLN (SD 3063.9 PLN), calculated using the GVA; 
and €322.62 (SD €317.21) or 1348.55 PLN (SD 1325.95 
PLN) calculated using the GI (Table 4).
The total indirect costs as well as their components 
(absenteeism and presenteeism) differed significantly 
between patients with disease in remission (or mild activ-
ity) and those with active disease, as assessed by an expert 
clinician (Table 5).
The patients’ quality of life expressed as utility was cor-
related with absenteeism and presenteeism (a correlation of 
−0.537 and −0.682, with P values of 0.002 and <0.001, 
respectively, which indicates statistical significance). Util-
ity showed a significant negative moderate-to-strong cor-
relation with absenteeism, presenteeism and total indirect 
costs (correlation of −0.772; P value of <0.001). This sug-
gests that a higher quality of life was associated with lower 
indirect costs. The disease activity score was significantly 
correlated with indirect costs (positive correlation of 0.618 
for absenteeism, of 0.838 for presenteeism and of 0.864 for 
total costs; P values of <0.0001) and quality of life (nega-
tive correlation of −0.878; P value of <0.0001). The qual-
ity of life and disease activity were significantly correlated 
with presenteeism and absenteeism (Table 6).
Discussion
Although PsA is believed to impose a high clinical and 
societal burden and reduce the quality of life, especially 
in active disease state, there is no evidence to confirm 
this in Poland. Moreover, PsA is known to generate sig-
nificant indirect costs, mainly due to presenteeism. Our 
study showed a significant moderate-to-strong correlation 
between disease activity and indirect costs (total costs as 
well as those of absenteeism and presenteeism).
Table 3  Number of patients reporting problems in specific life 
domains included in the EQ-5D-3L questionnaire
Life domain Problems reported with specific life domains
No Some A lot
Mobility 27 (54 %) 20 (40 %) 3 (6 %)
Self-care 33 (66 %) 15 (30 %) 2 (4 %)
Usual activities 18 (36 %) 28 (56 %) 4 (8 %)
Pain 13 (26 %) 34 (68 %) 3 (6 %)
Anxiety 26 (52 %) 21 (42 %) 3 (6 %)
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To our knowledge, our study is the first to measure indi-
rect costs of PsA in Polish patients. Therefore, we deemed 
it necessary to assess a societal burden of PsA in Poland 
using a comprehensive approach. Moreover, in the absence 
of reliable data on the health-related quality of life and util-
ity of patients with PsA in Poland, we believed that a study 
that would provide such information was urgently needed. 
Our project involved the assessment of the indirect costs of 
absenteeism and presenteeism, based on the WPAI ques-
tionnaire. The methodology used in our study allowed us to 
obtain novel data that fill the information gap.
Our study revealed that there may be substantial indirect 
costs related to PsA. The society can suffer from productiv-
ity loss reaching €484.56 per working patient per month, 
which may give rise to a considerable amount when taking 
into account the prevalence of the disease. In addition, our 
study showed that both disease activity and quality of life 
can be important factors influencing total indirect costs.
In order to compare our results with findings of other 
investigators, we performed a review of medical databases 
to identify relevant sources of data on indirect costs of PsA 
reported elsewhere [11]. The search was conducted using 
MEDLINE (via PubMed), Embase and Centre for Reviews 
and Dissemination databases and included original studies, 
systematic reviews, economic evaluations, as well as con-
ference abstracts and posters. We identified 8 records (7 
studies) presenting indirect costs of PsA from the follow-
ing European countries: Spain [12], Hungary [13, 14], Ger-
many [15], Italy [16], Czech Republic [17], Norway [18] 
and Hong Kong [19]. Among the identified records, there 
were 5 economic evaluations, 2 conference abstracts and 1 
poster.
We observed a large variety of indirect resources and cal-
culation methods used in the identified records. All of the 
identified studies took into account absenteeism, although 
its components differed. In addition, all of the identified 
studies included the cost of sick leave as part of indirect 
costs [12–19]. Early retirement (full-time disability pen-
sion) was considered in 5 studies [12–15, 17, 18]. The 
cost of patient assistance was considered in 2 studies [12, 
16]. In addition, 1 study took into account out-of-pocket 
expenses incurred by patients due to PsA [12]; 1 study took 
into account part-time disability pension due to PsA [17]; 1 
study considered the cost of days off household work due to 
the disease [19]; and 2 studies took into account unemploy-
ment caused by PsA [12, 18]. None of the studies consid-
ered early death or presenteeism, as PsA is not a relevant 
cause of premature death. Of all the identified studies, 3 
used the HCA [13, 14, 16, 19], 1 used the FCA [19], and 
2 provided calculations based on both approaches [15, 18]. 
Only 1 study did not specify the methodology for the esti-
mation of indirect costs [12]. The number of patients varied 
among the identified studies from 61 [17] to 908 [15]. The 
euro (EUR; €) was the most common currency and was used 
in 6 of the studies [12–18]. Only 1 study used the US dollar 
(USD; $) as the currency [19]. However, all of those stud-
ies focused only on the assessment of indirect costs without 
assessing correlations with utility or disease activity.
In a conference abstract, Moreno et al. [12] considered 
indirect costs related to sick leave, early retirement, patient 
Table 4  Monthly indirect costs (in euro) due to PsA
Cost Correction factor Macroeconomic indicator Mean (SD) Median (Q1–Q3) Skewness
Absenteeism Yes GDP 67.4 (116.75) 18.98 (0–18.98) 2.35
GVA 158 (273.68) 44.5 (0–44.5)
GI 68.38 (118.44) 19.26 (0–19.26)
No GDP 103.69 (179.61) 29.2 (0–29.2)
GVA 243.07 (421.05) 68.46 (0–68.46)
GI 105.19 (182.22) 29.63 (0–29.63)
Presenteeism Yes GDP 139.31 (128.92) 115.79 (57.89–115.79) 0.87
GVA 326.56 (302.21) 271.43 (135.71–271.43)
GI 141.33 (130.79) 117.47 (58.73–117.47)
No GDP 214.32 (198.33) 178.13 (89.07–178.13)
GVA 502.4 (464.94) 417.58 (208.79–417.58)
GI 217.42 (201.21) 180.72 (90.36–180.72)
Total cost Yes GDP 206.7 (203.24) 134.29 (62.64–134.29) 1.39
GVA 484.56 (476.44) 314.81 (146.84–314.81)
GI 209.7 (206.19) 136.24 (63.55–136.24)
No GDP 318.01 (312.68) 206.61 (96.37–206.61)
GVA 745.48 (732.99) 484.33 (225.91–484.33)
GI 322.62 (317.21) 209.6 (97.76–209.6)
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assistance and out-of-pocket expenses paid by the patient 
due to PsA. Cost data were obtained from 287 patients in 
Spain and expressed in euros (2008). The methodology 
used for the calculation of indirect costs was not specified. 
The mean annual indirect cost per patient was reported to 
reach €1261 (95 % CI €581–€1987) [1].
Brodszky et al. [13, 14] analysed indirect costs associ-
ated with sick leave and early retirement, calculated with 
the HCA. Cost data were obtained from 183 patents in 
Hungary and presented as 2007 euros; the mean annual 
indirect cost per patient was €2904 (SD €4899) [13, 14].
Huscher et al. [15] considered sick leave and early 
retirement as components of indirect costs calculated using 
both the HCA and FCA. Cost data were obtained from 908 
patients with PsA in Germany and expressed in 2002 euros. 
They reported the mean annual indirect costs per patient of 
€1374 (SD €4447) for sick leave (calculation methodology 
was not specified). The average annual cost of permanent 
work disability was €6545 (SD €13,596) and €1040 (SD 
€2160) using the HCA and FCA, respectively [15].
Olivieri et al. [16] analysed sick leave and patient assis-
tance as components of indirect costs calculated using the 
HCA. Cost data were obtained from 107 patients with PsA 
in Italy and presented as 2007 euros. The study presented 
a cost-effectiveness analysis of tumour necrosis factor 
inhibitors in the therapy of patients with PsA. The cost was 
presented as a baseline value of €576.30 (SD €1565.11; 
95 % CI €276.33–€876.28) for 6 months [16].
In a conference poster prepared for ISPOR 2010, Klimes 
and Dolezal [17] reported findings on indirect costs related 
to sick leave, early retirement and part-time disability pen-
sions of patients with PsA. Costs were obtained from 61 
patients in the Czech Republic, calculated using the FCA 
and expressed in 2009 euro [17].
Kvamme et al. [18] considered the indirect costs related 
to sick leave, early retirement and unemployment, cal-
culated using both the HCA and FCA. Cost data were 
obtained from 374 patients in Norway, including 311 
patients treated with synthetic disease-modifying antirheu-
matic drugs and 63 patients treated with biologic disease-
modifying antirheumatic drugs. Cost data were presented 
in 2011 euro [18]. The study compared the indirect costs 
for patients with PsA treated with synthetic or biologic 
disease-modifying antirheumatic drugs. The average pro-
ductivity loss over 2 years per patient was €58,215 and 
€74,009 for synthetic and biologic drugs, respectively, cal-
culated using the HCA, and the average productivity loss 
over 2 years per patient was €14,209 and €17,948 for syn-
thetic and biologic drugs, respectively, calculated using the 
FCA.
Our study has several limitations. First, it was designed 
to survey a heterogeneous group of patients with PsA. The 
Table 5  Monthly indirect costs (in euro) due to PsA depending on disease activity assessed by an expert clinician
Cost Correction 
factor
Macro-
economic 
indicator
Disease activity P value
Remission/mild Active
Mean (SD) Median (Q1–Q3) Mean (SD) Median (Q1–Q3)
Absenteeism Yes GDP 18.98 (31.05) 0 (0–23.73) 149.24 (165.9) 70 (34.40–313.19) 0.0004*
GVA 44.5 (72.78) 0 (0–55.62) 349.85 (388.91) 164.08 (80.65–734.19)
GI 19.26 (31.5) 0 (0–24.07) 151.41 (168.31) 71 (34.90–317.74)
No GDP 29.2 (47.76) 0 (0–36.50) 229.6 (255.23) 107.68 (52.93–481.84)
GVA 68.46 (111.96) 0 (0–85.57) 538.24 (598.32) 252.43 (124.08–1129.53)
GI 29.63 (48.45) 0 (0–37.03) 232.93 (258.93) 109.24 (53.7–488.82)
Presenteeism Yes GDP 88.22 (85.12) 57.89 (0–115.79) 254.73 (139.69) 260.52 (101.31–405.25) 0.0026*
GVA 206.8 (199.55) 135.71 (0–271.43) 597.14 (327.47) 610.72 (237.5–950)
GI 89.5 (86.36) 58.73 (0–117.47) 258.43 (141.72) 264.3 (102.78–411.13)
No GDP 135.72 (130.96) 89.07 (0–178.13) 391.89 (214.91) 400.8 (155.87–623.47)
GVA 318.16 (307) 208.79 (0–417.58) 918.68 (503.8) 939.57 (365.39–1461.54)
GI 137.69 (132.86) 90.36 (0–180.72) 397.58 (218.03) 406.61 (158.13–632.51)
Total cost Yes GDP 107.2 (96.2) 76.87 (0–191.71) 403.972 (232.07) 402.41 (258.86–523.77) 0.0004*
GVA 251.3 (225.5) 180.21 (0–449.42) 946.999 (544.02) 943.33 (606.82–1227.83)
GI 108.75 (97.59) 77.99 (0–194.49) 409.831 (235.44) 408.24 (262.61–531.36)
No GDP 164.92 (147.99) 118.27 (0–294.94) 621.496 (357.03) 619.09 (398.24–805.8)
GVA 386.62 (346.93) 277.25 (0–691.41) 1456.92 (836.96) 1451.27 (933.57–1888.97)
GI 167.32 (150.14) 119.98 (0–299.22) 630.509 (362.21) 628.06 (404.02–817.48)
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methods for the inclusion of respondents with randomised 
allocation might have made the results of the study fully 
representative for the Polish population of patients with 
PsA; however, a relatively small number of patients lim-
ited the results. A larger study based on the same protocol 
is therefore needed to provide more reliable data. Second, 
as there is no specific scale to assess the disease activity of 
PsA, we assessed the disease activity with our own ques-
tionnaire developed on the basis of an adjusted BASDAI. 
This may constitute another limitation because the ques-
tionnaire has not been validated.
Despite a relatively small population of patients, our 
findings are comparable to those from other countries. 
The results of our study reflect the real impact of PsA on 
the economic development of Poland and allow a reliable 
economic analysis that is required for the development of 
clinical practice guidelines, optimal in terms of resource 
allocation. The results of our study have a wide applica-
tion as they can be used to inform economic models created 
to assess cost-effectiveness of a new treatment in Poland, 
increasing the odds for a positive reimbursement decision.
Conclusions
PsA imposes a personal burden and affects the patient’s 
ability to work. Moreover, it generates considerable indi-
rect costs, mainly due to lower productivity at work, as well 
as reduces the patients’ quality of life. Further studies, with 
a fully representative population of patients, are needed to 
elucidate the relation between the quality of life, disease 
activity and indirect costs of disease in patients with PsA 
in Poland.
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